Sorrento Approved For $105M Scilex Stock Sale In Ch. 11
Bankrupt drug developer Sorrento Therapeutics received approval Friday in Texas court for a $105 million sale of its stake in subsidiary Scilex Holding Co. after a bankruptcy judge declined to reopen...To view the full article, register now.
Already a subscriber? Click here to view full article